Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.38 |
| ▸ | CDC25B | P30305 | 8/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | GJB2 | P29033 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937697 | 1.00 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL17106780 | 1.00 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL19343951 | 1.00 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL22002160 | 1.00 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL17106842 | 0.86 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL17106843 | 0.86 | HTR1A (0.41) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL29937393 | 0.85 | HTR1A (0.43) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL17106818 | 0.85 | HTR1A (0.43) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL29937871 | 0.85 | HTR1A (0.43) | HTR1APTPN1CDC25BPDE2ABCHE | |
| SCHEMBL25598746 | 0.85 | HTR1A (0.43) | HTR1APTPN1CDC25BPDE2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3122752-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015143712-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-8987709-B2 | Arylene containing polymer and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | HTR1A 4006/4885PTPN1 3398/4885CDC25B 1008/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | HTR1A 2118/4885PTPN1 922/4885CDC25B 2277/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | HTR1A 4006/4885PTPN1 3398/4885CDC25B 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.